Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 90

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 90
---
common stock on such exchange; our ability to comply with regulation by various federal, state, local and foreign governmental agencies
and to maintain necessary regulatory clearances or approvals; and the other risks and uncertainties described in the Risk Factors section
of our Annual Report on Form 10-K for the period ended December 31, 2024, as filed with the Securities and Exchange Commission (“SEC”)
on March 31, 2025, and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of this
Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from
time to time, whether as a result of new information, future developments or otherwise.

Available Information

From time to time, we use press releases, X (formerly
Twitter) (@endralifesci) and LinkedIn (www.linkedin.com/company/endra-inc) to distribute material information. Our press releases and
financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.
Accordingly, investors should monitor these channels, in addition to our SEC filings and public conference calls and webcasts. In addition,
investors may automatically receive e-mail alerts and other information about the Company by enrolling their e-mail addresses by visiting
the “Email Alerts” section of our website at investors.endrainc.com. Information that is contained in and can be accessed
through our website, X posts and LinkedIn are not incorporated into, and do not form a part of, this Quarterly Report or any other report
or document we file with the SEC.

15

Overview

We are developing a thermo-acoustic medical device
designed specifically for accurate liver fat measurement for metabolic disease detection and management and GLP-1 drug eligibility and
management. Our goal is to create the next-generation enhanced ultrasound technology platform designed to establish key biomarkers for
metabolic diseases management and emerging GLP-1 therapies.

Our medical device business model will primarily
be a low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue (MRR), while also offering a traditional
product sale with annual upgrade and maintenance fees. These sales are expected to be made by a direct sales force to four markets:

    1. 
    Pharmaceutical Companies and Clinical Research Organizations (“CROs”) - to assist them in the efficient screening and monitoring subjects for new GLP-1, NASH/MASH and Insulin